BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22833638)

  • 1. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.
    Huang TD; Berhin C; Bogaerts P; Glupczynski Y
    J Antimicrob Chemother; 2012 Nov; 67(11):2696-9. PubMed ID: 22833638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde AM; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    J Antimicrob Chemother; 2017 May; 72(5):1359-1363. PubMed ID: 28108677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
    Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a university hospital in south-western Germany.
    Wienke M; Pfeifer Y; Weissgerber P; Marschal M; Autenrieth IB; Gröbner S
    Chemotherapy; 2012; 58(3):241-8. PubMed ID: 22832033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.
    Naesens R; Ursi JP; Van Schaeren J; Jeurissen A
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):381-4. PubMed ID: 18802728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
    Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):217-21. PubMed ID: 23522845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility.
    Roy S; Datta S; Viswanathan R; Singh AK; Basu S
    J Antimicrob Chemother; 2013 May; 68(5):1036-42. PubMed ID: 23335112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
    Fernández-Canigia L; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
    Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
    J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals.
    Ko KS; Lee MY; Song JH; Lee H; Jung DS; Jung SI; Kim SW; Chang HH; Yeom JS; Kim YS; Ki HK; Chung DR; Kwon KT; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2008 Aug; 61(4):453-9. PubMed ID: 18482815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.